- December: New Imported Drug Approvals by the NMPA - November 2024
- □ Belzutifan Tablets (Brand; WELIREG) – marketed by MERCK SHARP & DOHME (UK) LIMITED
- □ Varenicline Tartrate Nasal Spray (Brand; N/A) – marketed by Oyster Point Pharma, Inc.
- □ Ambroxol Hydrochloride Spray (Brand; N/A) – marketed by GMep Medical Technology GmbH
- □ Minocycline Hydrochloride Foam (Brand; N/A) – marketed by Journey Medical Corporation
- □ Efgartigimod Alfa Injection (SubQ) (Brand; VYVGART HYTRULO) – marketed by argenx BV
- □ Rilonacept for Injection (Brand; ARCALYST) – marketed by Kiniksa Pharmaceuticals (UK),Ltd.
- □ Mirvetuximab Soravtansine Injection (Brand; ELAHERE) – marketed by ImmunoGen, Inc.
- □ Recombinant Human Papillomavirus Quadrivalent Vaccine (Brand; GARDASIL) – marketed by Merck Sharp & Dohme LLC
(Source: BaiPharm)